Connect on Social Media
LinkedIn:
Twitter:
Facebook:
About
First Name:
Last Name:
Title and Organization:
Bio:
Dena Grayson, MD, PhD (née Dena Minning) is a physician-scientist with strong leadership skills, clear strategic vision, proven drug development and medical affairs expertise, and an outstanding ability to work cross-functionally and deliver under tight timelines. She led the successful early clinical development of Repatha (evolocumab), approved for the treatment of hypercholesteremia. Dr. Grayson also played a role in the successful development of Orladeyo (berotralstat), approved for the treatment of hereditary angioedema (HAE). She has built and led high-functioning, cross-functional teams and has successfully led development programs of small and large molecule therapeutics in hematology (anemia, non-Hodgkin lymphoma, multiple myeloma, myeloproliferative disorders, acute leukemia, and other B- and T-cell malignancies), oncology (gastric, colorectal, and pancreatic carcinomas), nephrology, cardiology, metabolism, inflammatory and autoimmune diseases (lupus nephritis, ANCA vasculitis, asthma, rheumatoid arthritis), infectious diseases, biodefense, neurology, and rare diseases, including paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), IgA nephropathy (IgAN), primary membranous nephritis (PMN), lupus nephritis, atypical hemolytic uremic syndrome (aHUS), and other indications. Dr. Grayson’s experience in medical affairs includes identifying and managing key opinion leaders and stakeholders, developing and managing advisory boards, developing clinical and scientific research studies to support pipeline and marketed products, medical and scientific communication, and translating key scientific and clinical findings to drive commercial strategies for approved and developmental-stage products in hematology, oncology, and nephrology. Dr. Grayson played a key leadership role in successfully raising over $120 million for several biotechnology companies. Her research has been published in prominent journals, such as Nature, and featured in the New York Times.
Fellowship Program
Class
